RECRUITINGINTERVENTIONAL
The Effect of Cord Blood Serum Eyes Drops Administer in Patients With Severe Keratopathy Related to EGFR-I Treatment
Personalized Approach in the Treatment of Patients Affected by Severe Dry Eye Associated With Therapy With EGFR Inhibitors (EGRFR-I) With Growth Factors in Cord Blood Serum (CBS) Eye Drops
About This Trial
The study aim to evaluate the efficacy of cord blood eye drops in the healing of the damaged corneal epithelium.
Who May Be Eligible (Plain English)
Who May Qualify:
- age over 18 years
- oncology and advanced cancer patients who have EGFr mutation and who require treatment with antiEGFr drugs
- signing of willing to sign a consent form
Who Should NOT Join This Trial:
- Patients who are unable to store/administer the CSCO independently, or with the help of care-givers.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* age over 18 years
* oncology and advanced cancer patients who have EGFr mutation and who require treatment with antiEGFr drugs
* signing of informed consent
Exclusion Criteria:
* Patients who are unable to store/administer the CSCO independently, or with the help of care-givers.
Treatments Being Tested
DRUG
administration cord blood based eye drops, standardized to the deliver BDNF.
administration cord blood based eye drops customized to deliver epitelio tropic factors, incluiding EGF in EGFR blocked cells
Locations (1)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy